Spyre Therapeutics (SYRE) News Today → Collapse of the Petrodollar (From Colonial Metals) (Ad) Free SYRE Stock Alerts $33.67 -0.94 (-2.72%) (As of 06/7/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 4, 2024 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Trading Down 8.4%Spyre Therapeutics (NASDAQ:SYRE) Shares Down 8.4%June 3, 2024 | prnewswire.comSpyre Therapeutics Announces Grants of Inducement AwardsMay 30, 2024 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Trading Up 5.8%Spyre Therapeutics (NASDAQ:SYRE) Stock Price Up 5.8%May 29, 2024 | prnewswire.comSpyre Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 23, 2024 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Trading Down 5.5%Spyre Therapeutics (NASDAQ:SYRE) Trading Down 5.5%May 15, 2024 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Issues Earnings Results, Misses Estimates By $0.30 EPSSpyre Therapeutics (NASDAQ:SYRE - Get Free Report) released its earnings results on Monday. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.30).May 15, 2024 | prnewswire.comSpyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of DirectorsMay 15, 2024 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Short Interest UpdateSpyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) was the recipient of a significant increase in short interest in the month of April. As of April 30th, there was short interest totalling 4,380,000 shares, an increase of 23.0% from the April 15th total of 3,560,000 shares. Based on an average trading volume of 490,400 shares, the days-to-cover ratio is currently 8.9 days. Currently, 12.8% of the shares of the company are sold short.May 14, 2024 | markets.businessinsider.comPositive Outlook on Spyre Therapeutics’ IBD Pipeline and Financial StabilityMay 13, 2024 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Given New $40.00 Price Target at Wells Fargo & CompanyWells Fargo & Company increased their target price on Spyre Therapeutics from $35.00 to $40.00 and gave the company an "overweight" rating in a research note on Monday.May 10, 2024 | markets.businessinsider.comSpyre Therapeutics: Strong Buy Recommendation on Robust Pipeline and Financial StabilityMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed: Spyre Therapeutics’ Promising Pipeline and Expert Team Drive Positive OutlookMay 10, 2024 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Shares Gap Up on Analyst UpgradeSpyre Therapeutics (NASDAQ:SYRE) Shares Gap Up on Analyst UpgradeMay 10, 2024 | finanznachrichten.deSpyre Therapeutics, Inc.: Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 10, 2024 | investorplace.comSYRE Stock Earnings: Spyre Therapeutics Misses EPS for Q1 2024May 9, 2024 | chron.comSpyre Therapeutics: Q1 Earnings SnapshotMay 9, 2024 | prnewswire.comSpyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 7, 2024 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Shares Down 5.1% Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 5.1%May 3, 2024 | prnewswire.comSpyre Therapeutics Announces Grants of Inducement AwardsMay 3, 2024 | msn.comBaird Initiates Coverage of Spyre Therapeutics (SYRE) with Outperform RecommendationMay 3, 2024 | msn.comCarvana upgraded, Block downgraded: Wall Street's top analyst callsMay 2, 2024 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Now Covered by Robert W. BairdRobert W. Baird initiated coverage on shares of Spyre Therapeutics in a report on Thursday. They set an "outperform" rating and a $50.00 target price for the company.April 29, 2024 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Trading Up 6.1%Spyre Therapeutics (NASDAQ:SYRE) Shares Up 6.1%April 24, 2024 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Shares Down 5% Spyre Therapeutics (NASDAQ:SYRE) Shares Down 5%April 23, 2024 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of "Buy" by BrokeragesSpyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) has been given a consensus recommendation of "Buy" by the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 1-year price taApril 20, 2024 | investing.comSpyre Therapeutics Inc (SYRE)April 17, 2024 | msn.comSpyre Therapeutics (SYRE) Price Target Increased by 5.00% to 42.84April 5, 2024 | markets.businessinsider.comBuy Rating Affirmed for Spyre Therapeutics on Promising mAb Dosing and Market PositioningApril 1, 2024 | prnewswire.comSpyre Therapeutics Announces Grants of Inducement AwardsMarch 30, 2024 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Sees Large Growth in Short InterestSpyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) saw a large increase in short interest in March. As of March 15th, there was short interest totalling 2,880,000 shares, an increase of 34.0% from the February 29th total of 2,150,000 shares. Based on an average daily volume of 450,500 shares, the short-interest ratio is presently 6.4 days. Approximately 9.0% of the shares of the stock are short sold.March 29, 2024 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of "Buy" by AnalystsSpyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) has been given an average rating of "Buy" by the seven analysts that are currently covering the firm, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average 12-month price objective among brMarch 26, 2024 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Price Target Raised to $54.00Stifel Nicolaus lifted their price target on shares of Spyre Therapeutics from $36.00 to $54.00 and gave the stock a "buy" rating in a research note on Tuesday.March 25, 2024 | markets.businessinsider.comStrong Buy Rating for Spyre Therapeutics Based on Promising SPY001 Data and Financial PositionMarch 20, 2024 | investing.comSpyre Therapeutics secures $180 million in PIPE dealMarch 18, 2024 | markets.businessinsider.comSpyre Therapeutics Privately Places $180 Mln Of Shares; Stock Up In Pre-MarketMarch 18, 2024 | msn.comSpyre Therapeutics climbs 5%, prices $180M private financingMarch 18, 2024 | prnewswire.comSpyre Therapeutics Announces $180 Million Private PlacementMarch 6, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Humana (HUM), Alnylam Pharma (ALNY) and Spyre Therapeutics (SYRE)March 4, 2024 | msn.comHere's What Could Help Spyre Therapeutics (SYRE) Maintain Its Recent Price StrengthMarch 2, 2024 | finanznachrichten.deSpyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement AwardsMarch 1, 2024 | prnewswire.comSpyre Therapeutics Announces Grants of Inducement AwardsMarch 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX), Madrigal Pharmaceuticals (MDGL) and Spyre Therapeutics (SYRE)March 1, 2024 | markets.businessinsider.comBuy Rating for Spyre Therapeutics: Anticipated Clinical Trials and Strategic Advantages Propel OptimismMarch 1, 2024 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Upgraded at Wells Fargo & CompanyWells Fargo & Company upgraded shares of Spyre Therapeutics from an "equal weight" rating to an "overweight" rating and lifted their price objective for the stock from $12.00 to $35.00 in a research report on Friday.March 1, 2024 | finanznachrichten.deSpyre Therapeutics, Inc.: Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 1, 2024 | markets.businessinsider.comTD Cowen Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)February 29, 2024 | prnewswire.comSpyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateFebruary 26, 2024 | finance.yahoo.comSpyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care ConferenceFebruary 26, 2024 | prnewswire.comSpyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care ConferenceFebruary 8, 2024 | finance.yahoo.comSpyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation Get Spyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address $25,000 into $109,616 in two months? (Ad)Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time… Go here to watch the most recent trading workshop video at no charge. SYRE Media Mentions By Week SYRE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SYRE News Sentiment▼0.300.72▲Average Medical News Sentiment SYRE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SYRE Articles This Week▼22▲SYRE Articles Average Week Get Spyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BBIO News Today GRFS News Today CYTK News Today APLS News Today MDGL News Today ALPN News Today NUVL News Today ALKS News Today PRGO News Today CRNX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SYRE) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredWe’ve Made 1,000% … THREE Different Times in the Last Year (Here’s How)Bitcoin can and probably will hit the $1 MILLION level this decade. That’s more than 1,000% upside from the...Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | Sponsored